The potential for emerging therapeutic options for Clostridium difficile infection

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gut microbes

• Publication date

  2014-11-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/19490976.2014.983768PMID 25564777PMCID PMC4615897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.

  2014cited by this paper
• In vitro activity of MCB3681 against Clostridium difficile strains.

  2014influential reference
• Recombinant Clostridium difficile Toxin Fragments as Carrier Protein for PSII Surface Polysaccharide Preserve Their Neutralizing Activity

  2014cited by this paper
• 126An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In Vivo

  2014cited by this paper
• Vaccination against Clostridium difficile using toxin fragments

  2014cited by this paper
• Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection

  2014cited by this paper
• Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile

  2014cited by this paper
• Fidaxomicin Inhibits Clostridium difficile Toxin A-Mediated Enteritis in the Mouse Ileum

  2014cited by this paper
• Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection.

  2014influential reference
• Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure.

  2014influential reference
• Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A retrospective evaluation of 31 patients

  2014influential reference
• Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.

  2014cited by this paper
• Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection

  2014influential reference
• Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.

  2013cited by this paper
• Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope.

  2013influential reference
• Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.

  2013influential reference
• Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut

  2013cited by this paper
• Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B

  2013cited by this paper
• Clostridium difficile PSI polysaccharide: synthesis of pentasaccharide repeating block, conjugation to exotoxin B subunit, and detection of natural anti-PSI IgG antibodies in horse serum.

  2013cited by this paper
• Fecal Transplantation for the Treatment of Recurrent Clostridium Difficile Infection

  2013cited by this paper
• Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile

  2013cited by this paper
• Carbohydrate-based Clostridium difficile vaccines

  2013cited by this paper
• Analysis of Anti-Clostridium difficile Activity of Thuricin CD, Vancomycin, Metronidazole, Ramoplanin, and Actagardine, both Singly and in Paired Combinations

  2013cited by this paper
• Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate

  2013cited by this paper
• Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland

  2013cited by this paper
• Fidaxomicin inhibits toxin production in Clostridium difficile.

  2013cited by this paper
• Intracolonic Vancomycin for Severe Clostridium difficile Colitis

  2013cited by this paper
• A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

  2013influential reference
• High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria

  2013influential reference
• Role of Fidaxomicin for the Treatment of Clostridium difficile Infection

  2013cited by this paper
• Duodenal infusion of donor feces for recurrent Clostridium difficile.

  2013cited by this paper
• Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile

  2013cited by this paper
• Toll-Like Receptor 5-Dependent Immunogenicity and Protective Efficacy of a Recombinant Fusion Protein Vaccine Containing the Nontoxic Domains of Clostridium difficile Toxins A and B and Salmonella enterica Serovar Typhimurium Flagellin in a Mouse Model of Clostridium difficile Disease

  2013influential reference
• Investigating the candidacy of a lipoteichoic acid-based glycoconjugate as a vaccine to combat Clostridium difficile infection

  2013cited by this paper
• Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

  2012cited by this paper
• Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice

  2012cited by this paper
• Fidaxomicin Inhibits Spore Production in Clostridium difficile

  2012cited by this paper
• Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

  2012cited by this paper
• Discovery of LFF571: an investigational agent for Clostridium difficile infection.

  2012cited by this paper
• A Chimeric Toxin Vaccine Protects against Primary and Recurrent Clostridium difficile Infection

  2012influential reference
• Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing

  2012cited by this paper
• Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization.

  2012cited by this paper
• Fidaxomicin: a new option for the treatment of Clostridium difficile infection.

  2012cited by this paper
• Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin

  2012cited by this paper
• Burden of Clostridium difficile on the Healthcare System

  2012cited by this paper
• Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

  2012cited by this paper
• TcdC Does Not Significantly Repress Toxin Expression in Clostridium difficile 630ΔErm

  2012cited by this paper
• Generation of an actagardine A variant library through saturation mutagenesis

  2012cited by this paper
• A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study To Assess the Safety and Tolerability of LFF571 in Healthy Volunteers

  2012cited by this paper
• Efficacy of LFF571 in a Hamster Model of Clostridium difficile Infection

  2012cited by this paper
• Clostridium difficile infection

  2012cited by this paper
• Prospective Observational Study Comparing Three Different Treatment Regimes in Patients with Clostridium difficile Infection

  2012cited by this paper
• Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.

  2012cited by this paper
• Sustained Clinical Response as an Endpoint in Treatment Trials of Clostridium difficile-Associated Diarrhea

  2012cited by this paper
• Phosphorylation of the synthetic hexasaccharide repeating unit is essential for the induction of antibodies to Clostridium difficile PSII cell wall polysaccharide.

  2012cited by this paper
• Fecal microbiota transplantation in relapsing Clostridium difficile infection

  2012cited by this paper
• Clostridium difficile carbohydrates: glucan in spores, PSII common antigen in cells, immunogenicity of PSII in swine and synthesis of a dual C. difficile-ETEC conjugate vaccine.

  2012cited by this paper
• Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection.

  2012cited by this paper
• Nitazoxanide

  2012cited by this paper
• The role of toxin A and toxin B in the virulence of Clostridium difficile.

  2012cited by this paper
• Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.

  2012influential reference
• In Vivo Selection of Rifamycin-Resistant Clostridium difficile during Rifaximin Therapy

  2012cited by this paper
• Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA)

  2011influential reference
• The Anti-Sigma Factor TcdC Modulates Hypervirulence in an Epidemic BI/NAP1/027 Clinical Isolate of Clostridium difficile

  2011cited by this paper
• Fidaxomicin versus vancomycin for Clostridium difficile infection.

  2011cited by this paper
• A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic.

  2011cited by this paper
• Treating Clostridium difficile infection with fecal microbiota transplantation.

  2011cited by this paper
• Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile.

  2011influential reference
• Case Series

  2010cited by this paper
• Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial

  2010cited by this paper
• Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

  2010cited by this paper
• Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production

  2010cited by this paper
• A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.

  2010cited by this paper
• Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon

  2010cited by this paper
• Studies with bioengineered Nisin peptides highlight the broad‐spectrum potency of Nisin V

  2010cited by this paper
• Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole.

  2010cited by this paper
• Fecal Bacteriotherapy for Relapsing Clostridium difficile Infection in a Child: A Proposed Treatment Protocol

  2010cited by this paper
• Randomized Clinical Trial in Clostridium difficile Infection Confirms Superiority of Fidaxomicin Over Vancomycin

  2010cited by this paper
• Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.

  2010influential reference
• Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection

  2010influential reference
• Tigecycline Exhibits Inhibitory Activity against Clostridium difficile in the Colon of Mice and Does Not Promote Growth or Toxin Production

  2010cited by this paper
• Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

  2010cited by this paper
• Failure of Tigecycline to Treat Severe Clostridium Difficile Infection

  2010influential reference
• The role of toxin A and toxin B in Clostridium difficile infection

  2010cited by this paper
• Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy: A Case Series of 12 Patients

  2010cited by this paper
• European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

  2009cited by this paper
• Clostridium difficile-associated disease and mortality among the elderly critically ill

  2009cited by this paper
• Toxin B is essential for virulence of Clostridium difficile

  2009cited by this paper
• Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

  2009influential reference
• A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

  2009influential reference
• Truncation in the tcdC region of the Clostridium difficile PathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A

  2009cited by this paper
• Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection.

  2009influential reference
• Rifamycin Antibiotics for Treatment of Clostridium difficile–Associated Diarrhea

  2008cited by this paper
• Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses

  2008cited by this paper
• Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

  2008influential reference
• Altes und Neues zur antibiotikaassoziierten Diarrhö

  2008cited by this paper
• Clostridium difficile cell-surface polysaccharides composed of pentaglycosyl and hexaglycosyl phosphate repeating units.

  2008cited by this paper
• Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

  2008cited by this paper
• Clostridium difficile toxin synthesis is negatively regulated by TcdC.

  2008influential reference
• Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains.

  2007cited by this paper

• Synergistic and off-target effects of bacteriocins in a simplified human intestinal microbiome: implications for Clostridioides difficile infection control

  2025cites this paper
• Probiotics for Prevention and Treatment of Clostridium difficile Infection.

  2024cites this paper
• Encapsulation protocol for fecal microbiota transplantation

  2024influential citation
• Factores clínicos y epidemiológicos asociados a la infección por Clostridioides difficile en un hospital de tercer nivel en la ciudad de Medellín-Colombia

  2023cites this paper
• Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection

  2022cites this paper
• Bacteriocins: Properties and potential use as antimicrobials

  2021cites this paper
• Bacteriocins From LAB and Other Alternative Approaches for the Control of Clostridium and Clostridiodes Related Gastrointestinal Colitis

  2020cites this paper
• Identification of Simplified Microbial Communities That Inhibit Clostridioides difficile Infection through Dilution/Extinction

  2020cites this paper
• Clostridium difficile infection: Description of NAP1/027 and non NAP1/027 strains in a high complexity center in Cali, Colombia, 2012-2015

  2019cites this paper
• Recent advances in the treatment of C. difficile using biotherapeutic agents

  2019cites this paper
• Advances in the diagnosis and treatment of Clostridium difficile infections

  2018cites this paper
• Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment

  2018cites this paper
• Novel Antimicrobials for the Treatment of Clostridium difficile Infection

  2018cites this paper
• Clostridioides difficile Biology: Sporulation, Germination, and Corresponding Therapies for C. difficile Infection

  2018cites this paper
• Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection.

  2018cites this paper
• Probiotics for Prevention and Treatment of Clostridium difficile Infection.

  2018cites this paper
• Oral probiotic combination of Lactobacillus and Bifidobacterium alters the gastrointestinal microbiota during antibiotic treatment for Clostridium difficile infection

  2018cites this paper
• Control of Clostridium difficile Infection by Defined Microbial Communities

  2017cites this paper
• Characterizing the endometrial microbiome by analyzing the ultra-low bacteria from embryo transfer catheter tips in IVF cycles: next generation sequencing (NGS) analysis of the 16S ribosomal gene

  2017cites this paper
• Glycopeptide resistance: Links with inorganic phosphate metabolism and cell envelope stress.

  2017cites this paper
• An update on antibody-based immunotherapies for Clostridium difficile infection

  2016cites this paper
• Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis

  2016cites this paper
• Screening of Bifidobacteria and Lactobacilli Able to Antagonize the Cytotoxic Effect of Clostridium difficile upon Intestinal Epithelial HT29 Monolayer

  2016cites this paper
• Length of Hospital Stay and Bed Occupancy Rates in Former Yugoslav Republics 1989–2015

  2016cites this paper
• Advances in the Microbiome: Applications to Clostridium difficile Infection

  2016cites this paper
• Biochemical Properties and Mechanism of Action of Enterocin LD3 Purified from Enterococcus hirae LD3

  2016cites this paper
• Use of Bacillus amyloliquefaciens for Clostridium perfringens and Clostridium difficile associated disease

  2016cites this paper
• Engineering novel lantibiotics to target gut pathogens

  2016cites this paper
• Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.

  2016cites this paper
• Coexisting cytomegalovirus infection in immunocompetent patients with Clostridium difficile colitis.

  2016cites this paper
• Clinically Relevant Growth Conditions Alter Acinetobacter baumannii Antibiotic Susceptibility and Promote Identification of Novel Antibacterial Agents

  2015cites this paper
• Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health

  2015cites this paper
• Ambush of Clostridium difficile Spores by Ramoplanin: Activity in an In Vitro Model

  2015cites this paper
• Current Awareness Bulletin-Infection Prevention and Control February – March 2015

  2015cites this paper
• Étude des riborégulateurs guanine et de l'impact des gènes qu'ils régulent sur la biologie de Clostridium difficile 630

  2015cites this paper
• Are Proton Pump Inhibitors Affecting Intestinal Microbiota Health?

  2015cites this paper
• Monitoring in real time the cytotoxic effect of Clostridium difficile upon the intestinal epithelial cell line HT29.

  2015cites this paper
• Bacterial whole genome sequencing: The future of clinical bacteriology

  2014cites this paper
• Clinical and Experimental Gastroenterology Dovepress

  year unknowncites this paper